Polycythemia Vera (PV) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025
Polycythemia Vera (PV) Emerging Therapy and TPP Insights Thelansis’s “Polycythemia Vera (PV) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Polycythemia Vera (PV) Overview Polycythemia vera (PV) is a myeloproliferative disorder that produces excessive red blood cells, white blood cells, and platelets, leading to elevated blood viscosity and various associated symptoms. The primary cause is the uncontrolled proliferation of red blood cells, often extending to white blood cells and platelets. While the exact origin of this abnormal stem cell expansion is debated, a somatic mutation known as JAK2-V617F in the JAK2 gene (9p24) is prevalent among most patients. However, less frequently, a somatic mutation in exon 12 of JAK2 c...